DOI QR코드

DOI QR Code

Ginsenoside Rg1 Induces Apoptosis through Inhibition of the EpoR-Mediated JAK2/STAT5 Signalling Pathway in the TF-1/Epo Human Leukemia Cell Line

  • Li, Jing (Laboratory of Stem Cells and Tissue Engineering, Department of Histology and Embryology, Chongqing Medical University) ;
  • Wei, Qiang (Laboratory of Stem Cells and Tissue Engineering, Department of Histology and Embryology, Chongqing Medical University) ;
  • Zuo, Guo-Wei (Key Laboratories of Clinical Diagnostics, Province and Ministry of Education, Chongqing Medical University) ;
  • Xia, Jing (Laboratory of Stem Cells and Tissue Engineering, Department of Histology and Embryology, Chongqing Medical University) ;
  • You, Zhi-Mei (Laboratory of Stem Cells and Tissue Engineering, Department of Histology and Embryology, Chongqing Medical University) ;
  • Li, Chun-Li (Institute of Life Sciences, Chongqing Medical University) ;
  • Chen, Di-Long (Laboratory of Stem Cells and Tissue Engineering, Department of Histology and Embryology, Chongqing Medical University)
  • Published : 2014.03.30

Abstract

Ginsenoside Rg1 is one effective anticancer and antioxidant constituent of total saponins of Panax ginseng (TSPG), which has been shown to have various pharmacological effects. Our previous study demonstrated that Rg1 had anti-tumor activity in K562 leukemia cells. The aim of this study was designed to investigate whether Rg1 could induce apoptosis in TF-1/Epo cells and further to explore the underlying molecular mechanisms. Here we found that Rg1 could inhibit TF-1/Epo cell proliferation and induce cell apoptosis in vitro in a concentration and time dependent manner. It also suppressed the expression of EpoR on the surface membrane and inhibited JAK2/STAT5 pathway activity. Rg1 induced up-regulation of Bax, cleaved caspase-3 and C-PAPR protein and down-regulation of Bcl-2 and AG490, a JAK2 specific inhibitor, could enhance the effects of Rg1. Our studies showed that EpoR-mediated JAK2/STAT5 signaling played a key role in Rg1-induced apoptosis in TF-1/Epo cells. These results may provide new insights of Rg1 protective roles in the prevention a nd treatment of leukemia.

Keywords

References

  1. Chen D, Zuo G, Li C, et al (2009). Total saponins of Panax ginseng (TSPG) promote erythroid differentiation of human CD34+ cells via EpoR-mediated JAK2/STAT5 signaling pathway. J Ethnopharmacol, 126, 215-20. https://doi.org/10.1016/j.jep.2009.08.043
  2. Gao Y, Deng J, Yu X-F, et al (2011). Ginsenoside Rg1 inhibits vascular intimal hyperplasia in balloon-injured rat carotid artery by down-regulation of extracellular signal-regulated kinase 2. J Ethnopharmacol, 138, 472-8. https://doi.org/10.1016/j.jep.2011.09.029
  3. Kilpivaara O, and Levine R (2008). JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science. Leukemia, 22, 1813-7. https://doi.org/10.1038/leu.2008.229
  4. Kitamura T, Tange T, Terasawa T, et al (1989). Establishment and characterization of a unique human cell line that proliferates dependently on GM-CSF, IL-3, or erythropoietin. J Cell Physiol, 140, 323-34. https://doi.org/10.1002/jcp.1041400219
  5. Kumar S M, Zhang G, Bastian B C, et al (2011). Erythropoietin receptor contributes to melanoma cell survival in vivo. Oncogene, 31, 1649-60.
  6. Lee H J, Daver N, Kantarjian H M, et al (2013). The Role of JAK Pathway Dysregulation in the Pathogenesis and Treatment of Acute Myeloid Leukemia. Clin Cancer Res, 19, 327-35. https://doi.org/10.1158/1078-0432.CCR-12-2087
  7. Li Q-F, Shi S-L, Liu Q-R, et al (2008). Anticancer effects of ginsenoside Rg1, cinnamic acid, and tanshinone IIA in osteosarcoma MG-63 cells: nuclear matrix downregulation and cytoplasmic trafficking of nucleophosmin. Int J Biochem Cell Biol, 40, 1918-29. https://doi.org/10.1016/j.biocel.2008.01.031
  8. Liu J, Cai S-Z, Zhou Y, et al (2012). Senescence as a consequence of ginsenoside rg1 response on k562 human leukemia cell Line. Asian Pac J Cancer Prev, 13, 6191-6. https://doi.org/10.7314/APJCP.2012.13.12.6191
  9. Lord J D, McIntosh B C, Greenberg P D, et al (2000). The IL-2 receptor promotes lymphocyte proliferation and induction of the c-myc, bcl-2, and bcl-x genes through the trans-activation domain of Stat5. J Immunol, 164, 2533-41. https://doi.org/10.4049/jimmunol.164.5.2533
  10. Ma Z-c, Gao Y, Wang Y-g, et al (2006). Ginsenoside Rg1 inhibits proliferation of vascular smooth muscle cells stimulated by tumor necrosis factor-$\alpha$. Acta Pharmacol Sin, 27, 1000-6. https://doi.org/10.1111/j.1745-7254.2006.00331.x
  11. O'Shea J J, Gadina M, and Schreiber R D (2002). Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell, 109, 121-31. https://doi.org/10.1016/S0092-8674(02)00701-8
  12. Pelletier S, Gingras S, Funakoshi-Tago M, et al (2006). Two domains of the erythropoietin receptor are sufficient for Jak2 binding/activation and function. Mol Cell Biol, 26, 8527-38. https://doi.org/10.1128/MCB.01035-06
  13. Raghavendran H R B, Sathyanath R, Shin J, et al (2012). Panax ginseng modulates cytokines in bone marrow toxicity and myelopoiesis: ginsenoside Rg1 partially supports myelopoiesis. PloS one, 7, 33733. https://doi.org/10.1371/journal.pone.0033733
  14. Salomons G S, Brady H J, Verwijs-Jansen M, et al (1997). The Baxalfa: Bcl-2 ratio modulates the response to dexamethasone in leukaemic cells and is highly variable in childhood acute leukemia. Int J Cancer, 71, 959-65. https://doi.org/10.1002/(SICI)1097-0215(19970611)71:6<959::AID-IJC9>3.0.CO;2-X
  15. Santos F P, and Verstovsek S (2011). JAK2 inhibitors: What's the true therapeutic potential? Blood reviews, 25, 53-63. https://doi.org/10.1016/j.blre.2010.10.004
  16. Shi S L, Li Q F, Liu Q R, et al (2009). Nuclear matrix protein, prohibitin, was down regulated and translocated from nucleus to cytoplasm during the differentiation of osteosarcoma MG-63 cells induced by ginsenoside Rg1, cinnamic acid, and tanshinone IIA (RCT). J Cell Biochem, 108, 926-34. https://doi.org/10.1002/jcb.22324
  17. Tam W F, Hahnel P S, Schuler A, et al (2013). STAT5 Is Crucial to Maintain Leukemic Stem Cells in Acute Myelogenous Leukemias Induced by MOZ-TIF2. Cancer Res, 73, 373-84. https://doi.org/10.1158/0008-5472.CAN-12-0255
  18. Verdier F, Walrafen P, Hubert N, et al (2000). Proteasomes regulate the duration of erythropoietin receptor activation by controlling down-regulation of cell surface receptors. J Biol Chem, 275, 18375-81. https://doi.org/10.1074/jbc.275.24.18375
  19. Walz C, Cross N C, Van Etten et al (2008). Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders. Leukemia, 22, 1320-34. https://doi.org/10.1038/leu.2008.133
  20. Wang C-Z, Aung H H, Ni M, et al (2007). Red American ginseng: ginsenoside constituents and antiproliferative activities of heat-processed Panax quinquefolius roots. Planta Med, 73, 669. https://doi.org/10.1055/s-2007-981524
  21. Wang Y, Ye X, Ma Z, et al (2008). Induction of cytochrome P450 1A1 expression by ginsenoside Rg1 and Rb1 in HepG2 cells. Eur J Pharmacol, 601, 73-8. https://doi.org/10.1016/j.ejphar.2008.10.057
  22. Warsch W, Walz C, Sexl V (2013). JAK of all trades: JAK2- STAT5 as novel therapeutic targets in BCR-ABL1+ chronic myeloid leukemia. Blood, 122, 2167-75. https://doi.org/10.1182/blood-2013-02-485573
  23. Wu P, Zhang N, Wang X, et al (2012). The erythropoietin/ erythropoietin receptor signaling pathway promotes growth and invasion abilities in human renal carcinoma cells. PloS one, 7, 45122. https://doi.org/10.1371/journal.pone.0045122
  24. Zamzami N, Brenner C, Marzo I, et al (1998). Subcellular and submitochondrial mode of action of Bcl-2-like oncoproteins. Oncogene, 16, 2265-82. https://doi.org/10.1038/sj.onc.1201989
  25. Zuo G, Guan T, Chen D, et al (2009). Total saponins of Panax ginseng induces K562 cell differentiation by promoting internalization of the erythropoietin receptor. Am J Chin Med, 37, 747-57. https://doi.org/10.1142/S0192415X09007211

Cited by

  1. Ginsenoside Rg1 attenuates invasion and migration by inhibiting transforming growth factor-β1-induced epithelial to mesenchymal transition in HepG2 cells vol.11, pp.4, 2014, https://doi.org/10.3892/mmr.2014.3098
  2. Ginsenoside 20(S)-Rg3 Targets HIF-1α to Block Hypoxia-Induced Epithelial-Mesenchymal Transition in Ovarian Cancer Cells vol.9, pp.9, 2014, https://doi.org/10.1371/journal.pone.0103887
  3. Potential Neuroprotective Activity of Ginseng in Parkinson’s Disease: A Review vol.10, pp.1, 2015, https://doi.org/10.1007/s11481-014-9569-6
  4. The Study of Mountain Ginseng-added High Fat Diet on Anti-Apoptosis of Skeletal Muscle vol.104, pp.3, 2015, https://doi.org/10.14578/jkfs.2015.104.3.383
  5. Proliferative and Inhibitory Activity of Siberian ginseng (Eleutherococcus senticosus) Extract on Cancer Cell Lines; A-549, XWLC-05, HCT-116, CNE and Beas-2b vol.16, pp.11, 2015, https://doi.org/10.7314/APJCP.2015.16.11.4781
  6. Angelica Sinensis Polysaccharide Induces Erythroid Differentiation of Human Chronic Myelogenous Leukemia K562 Cells vol.16, pp.9, 2015, https://doi.org/10.7314/APJCP.2015.16.9.3715
  7. Saponins from Chinese Medicines as Anticancer Agents vol.21, pp.10, 2016, https://doi.org/10.3390/molecules21101326
  8. Ginsenoside Rg1 protects human umbilical cord blood-derived stromal cells against tert-Butyl hydroperoxide-induced apoptosis through Akt–FoxO3a–Bim signaling pathway vol.421, pp.1-2, 2016, https://doi.org/10.1007/s11010-016-2786-y
  9. vol.32, pp.7, 2017, https://doi.org/10.1002/tox.22416
  10. The Effect of Transarterial Chemoembolization in Combination With Kang’ai Injection on Patients With Intermediate Stage Hepatocellular Carcinoma: A Prospective Study pp.1552-695X, 2017, https://doi.org/10.1177/1534735417734913
  11. Ginsenoside Rb1 inhibits hypoxia-induced epithelial-mesenchymal transition in ovarian cancer cells by regulating microRNA-25 vol.14, pp.4, 2017, https://doi.org/10.3892/etm.2017.4889
  12. vol.29, pp.1, 2018, https://doi.org/10.1080/09540105.2018.1490700
  13. Ginsenoside Rg3 Inhibition of Thyroid Cancer Metastasis Is Associated with Alternation of Actin Skeleton vol.21, pp.9, 2018, https://doi.org/10.1089/jmf.2017.4144
  14. for Inflammation-Related Chronic Diseases: A Review on the Modulations of Multiple Pathways vol.46, pp.05, 2018, https://doi.org/10.1142/S0192415X18500519
  15. Carbon nanotubes in the delivery of anticancer herbal drugs vol.13, pp.10, 2018, https://doi.org/10.2217/nnm-2017-0397